Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more
Mega Lifesciences Public Company Limited (MEGA-R) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.046x
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has a cash flow conversion efficiency ratio of 0.046x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (฿461.26 Million) by net assets (฿9.95 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mega Lifesciences Public Company Limited - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mega Lifesciences Public Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Philex Mining Corporation
PINK:PXMFF
|
0.006x |
|
Beijing InterAct Technology Co Ltd
SHE:300419
|
0.041x |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
0.054x |
|
Webjet Limited
PINK:WEBJF
|
0.200x |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
0.029x |
|
Shanghai Fudan Forward S&T Co Ltd
SHG:600624
|
-0.034x |
|
Origin Enterprises plc
PINK:ORENF
|
0.583x |
|
UCO Bank
NSE:UCOBANK
|
0.060x |
Annual Cash Flow Conversion Efficiency for Mega Lifesciences Public Company Limited (2011–2024)
The table below shows the annual cash flow conversion efficiency of Mega Lifesciences Public Company Limited from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ฿9.88 Billion | ฿2.40 Billion | 0.243x | +17.40% |
| 2023-12-31 | ฿9.30 Billion | ฿1.93 Billion | 0.207x | -8.96% |
| 2022-12-31 | ฿8.78 Billion | ฿2.00 Billion | 0.227x | -33.05% |
| 2021-12-31 | ฿8.03 Billion | ฿2.73 Billion | 0.340x | +45.53% |
| 2020-12-31 | ฿6.98 Billion | ฿1.63 Billion | 0.233x | -3.57% |
| 2019-12-31 | ฿6.18 Billion | ฿1.50 Billion | 0.242x | +50.75% |
| 2018-12-31 | ฿5.72 Billion | ฿919.36 Million | 0.161x | -9.14% |
| 2017-12-31 | ฿5.24 Billion | ฿927.00 Million | 0.177x | -34.37% |
| 2016-12-31 | ฿4.68 Billion | ฿1.26 Billion | 0.269x | +91.67% |
| 2015-12-31 | ฿4.33 Billion | ฿609.12 Million | 0.141x | -8.98% |
| 2014-12-31 | ฿3.98 Billion | ฿614.22 Million | 0.154x | +22.40% |
| 2013-12-31 | ฿3.69 Billion | ฿465.77 Million | 0.126x | -40.02% |
| 2012-12-31 | ฿1.63 Billion | ฿342.02 Million | 0.210x | +3.97% |
| 2011-12-31 | ฿1.32 Billion | ฿266.67 Million | 0.202x | -- |